Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Arecor Therapeutics PLC ( (GB:AREC) ) has shared an announcement.
Arecor Therapeutics PLC has delivered a trading update for 2024, showcasing a revenue increase to £5.1 million. The company is focused on its promising ultra-concentrated insulin, AT278, for diabetes management and an innovative oral peptide delivery platform, with the potential for significant industry impact. Arecor’s strategic decision to cease operations of its subsidiary, Tetris Pharma, and return the rights to Ogluo® to Xeris BioPharma Holdings marks a shift to concentrate on high-value opportunities. These initiatives highlight Arecor’s commitment to addressing unmet patient needs in large markets and driving value for stakeholders.
More about Arecor Therapeutics PLC
Arecor Therapeutics PLC is a globally focused biopharmaceutical company specializing in transforming patient care by introducing innovative medicines to the market. Utilizing its proprietary technology platform, Arestat™, Arecor is developing an internal portfolio of proprietary products, particularly in diabetes and other therapeutic areas, while collaborating with leading pharmaceutical and biotechnology firms.
YTD Price Performance: -20.41%
Average Trading Volume: 7,685
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £22.09M
For detailed information about AREC stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue